ArticleJournal of thrombosis and haemostasis : JTH2017
A decision model to estimate a risk threshold for venous thromboembolism prophylaxis in hospitalized medical patients.
Article in Journal of thrombosis and haemostasis : JTH, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Pharmacologic Thromboprophylaxis in Medical Inpatients: A Systematic Review and Network Meta-Analysis.JAMA network open · 2026Pooled it
- Evaluation of venous thromboembolism risk assessment models for hospital inpatients: the VTEAM evidence synthesis.Health technology assessment (Winchester, England) · 2024Pooled it
- Risk assessment models for venous thromboembolism in hospitalised adult patients: a systematic review.BMJ open · 2021Pooled it
- What constitutes high risk for venous thromboembolism? Determining an appropriate threshold to initiate prophylaxis.Journal of thrombosis and haemostasis : JTH · 2026Article
- Should we focus on sustainable thromboprophylaxis and avoid overuse of low-molecular-weight heparins?Research and practice in thrombosis and haemostasis · 2026Article
- Effectiveness and cost effectiveness of pharmacological thromboprophylaxis for medical inpatients: decision analysis modelling study.BMJ medicine · 2024Article
- Generalizability of COBRA: A Parsimonious Perioperative Venous Thromboembolism Risk Assessment Model.The Journal of surgical research · 2024Article
- Integrating economic considerations into cutpoint selection may help align clinical decision support toward value-based healthcare.Journal of the American Medical Informatics Association : JAMIA · 2023Article
- A systematic approach to venous thromboembolism prevention: a focus on UK experience.Research and practice in thrombosis and haemostasis · 2023Article
- Tailored Bayes: a risk modeling framework under unequal misclassification costs.Biostatistics (Oxford, England) · 2022Article
- Three myths about risk thresholds for prediction models.BMC medicine · 2019Article
- Venous thromboembolism incidence in the Ireland east hospital group: a retrospective 22-month observational study.BMJ open · 2019Observational
- Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States.PharmacoEconomics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Essentials Low risk patients don't require venous thromboembolism (VTE) prophylaxis; low risk is unquantified. We used a Markov model to estimate the risk threshold for VTE prophylaxis in medical inpatients. Prophylaxis was cost-effective for an average medical patient with a VTE risk of ≥ 1.0%. VTE prophylaxis can be personalized based on patient risk and age/life expectancy. SUMMARY: Background Venous thromboembolism (VTE) is a common preventable condition in medical inpatients. Thromboprophylaxis is recommended for inpatients who are not at low risk of VTE, but no specific risk threshold for prophylaxis has been defined. Objective To determine a threshold for prophylaxis based on risk of VTE. Patients/Methods We constructed a decision model with a decision-tree following patients for 3 months after hospitalization, and a lifetime Markov model with 3-month cycles. The model tracked symptomatic deep vein thromboses and pulmonary emboli, bleeding events and heparin-induced thrombocytopenia. Long-term complications included recurrent VTE, post-thrombotic syndrome and pulmonary hypertension. For the base case, we considered medical inpatients aged 66 years, having a life expectancy of 13.5 years, VTE risk of 1.4% and bleeding risk of 2.7%. Patients received enoxaparin 40 mg day
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.